➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: June 18, 2021

DrugPatentWatch Database Preview

SIKLOS Drug Profile

Email this page to a colleague

« Back to Dashboard

Which patents cover Siklos, and when can generic versions of Siklos launch?

Siklos is a drug marketed by Addmedica Sas and is included in one NDA.

The generic ingredient in SIKLOS is hydroxyurea. There are ten drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the hydroxyurea profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Siklos

A generic version of SIKLOS was approved as hydroxyurea by BARR on October 16th, 1998.

  Try Before You Buy

Summary for SIKLOS
Drug patent expirations by year for SIKLOS
Drug Prices for SIKLOS

See drug prices for SIKLOS

Recent Clinical Trials for SIKLOS

Identify potential brand extensions & 505(b)(2) entrants

Emory UniversityPhase 3
Global Health Uganda LTDPhase 3
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 3

See all SIKLOS clinical trials

US Patents and Regulatory Information for SIKLOS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Addmedica Sas SIKLOS hydroxyurea TABLET;ORAL 208843-002 Dec 21, 2017 RX Yes Yes   Try Before You Buy   Try Before You Buy   Try Before You Buy
Addmedica Sas SIKLOS hydroxyurea TABLET;ORAL 208843-001 Dec 21, 2017 RX Yes No   Try Before You Buy   Try Before You Buy   Try Before You Buy
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.